Jack Bendheim Sells 5,280 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 5,280 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $44.56, for a total value of $235,276.80. Following the transaction, the chief executive officer owned 54,960 shares in the company, valued at approximately $2,449,017.60. This trade represents a 8.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, November 13th, Jack Bendheim sold 8,801 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.47, for a total value of $391,380.47.
• On Wednesday, November 12th, Jack Bendheim sold 21,536 shares of Phibro Animal Health stock. The shares were sold at an average price of $45.23, for a total value of $974,073.28.
• On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The shares were sold at an average price of $45.29, for a total value of $1,734,742.87.
• On Friday, November 7th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $42.86, for a total value of $150,867.20.
• On Tuesday, November 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $43.10, for a total value of $151,712.00.
• On Thursday, October 30th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.07, for a total transaction of $144,566.40.
• On Tuesday, October 28th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.56, for a total transaction of $146,291.20.
• On Thursday, October 23rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.18, for a total transaction of $141,433.60.
• On Wednesday, October 22nd, Jack Bendheim sold 11,859 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.27, for a total transaction of $477,561.93.
• On Monday, October 20th, Jack Bendheim sold 16,075 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.38, for a total transaction of $649,108.50.

Phibro Animal Health Trading Down 4.6%

Shares of NASDAQ:PAHC opened at $41.38 on Thursday. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. The stock’s 50-day moving average is $40.59 and its 200-day moving average is $32.40. The company has a market cap of $1.68 billion, a P/E ratio of 35.07, a P/E/G ratio of 1.24 and a beta of 0.81. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.15. The business had revenue of $363.89 million during the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities research analysts predict that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th will be given a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend is Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio is currently 28.92%.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Hughes Financial Services LLC bought a new stake in Phibro Animal Health in the third quarter valued at $40,000. Financial Management Professionals Inc. acquired a new stake in shares of Phibro Animal Health in the 2nd quarter valued at $32,000. National Bank of Canada FI bought a new stake in shares of Phibro Animal Health in the 1st quarter worth about $30,000. iSAM Funds UK Ltd acquired a new stake in shares of Phibro Animal Health during the 3rd quarter worth about $61,000. Finally, Advisory Services Network LLC acquired a new stake in shares of Phibro Animal Health during the 3rd quarter worth about $96,000. Institutional investors own 99.34% of the company’s stock.

Wall Street Analysts Forecast Growth

PAHC has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Bank of America increased their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a research note on Friday, August 29th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Morgan Stanley set a $34.00 price objective on Phibro Animal Health in a research report on Thursday, August 28th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.